CervoMed Completes Enrollment in Phase 2 Neflamapimod Study for Rare Dementia
CRVO sits 61% above its 52-week low of $2.13.
Summary
CervoMed completed enrollment in its Phase 2a trial of neflamapimod for nfvPPA, a rare frontotemporal dementia with no approved treatments. Interim biomarker data will be presented at the CTAD conference in November 2026, with first clinical data expected in Q1 2027. The trial enrolled 25 patients across leading U.S. academic centers. This follows the company's recent $10.5 million private placement and $10 million registered direct offering, which extended its cash runway into Q2 2027. A recent Nature Neuroscience publication supports the drug's mechanism, showing p38α inhibition reverses tau-driven neuronal deficits in preclinical models. The upcoming CTAD presentation is a key catalyst for validating the drug's potential in this indication.
At the time of this announcement, CRVO was trading at $3.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.1M. The 52-week trading range was $2.13 to $13.13. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.